Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.

Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure

Investors are optimistic about Boston Scientific's (BSX) strong improvement in organic sales, indicating a solid rebound in the legacy business.

Here's Why You Should Buy Boston Scientific (BSX) Stock

Centene

Elevance Health Inc

HCA Healthcare

Humana

Intuitive Surgical

Surgery Partners

Smith & Nephew

Tenet Healthcare

UnitedHealth Group

Zimmer Biomet Hlds

After a pandemic pause, hip and knee replacements are back. Long-postponed surgeries are being rescheduled, which is bad for business at insurance companies like UnitedHealth Group Inc. NYSE: UNH, but potentially good business for surgery centers like Surgery Partners Inc. NASDAQ: SGRY and companies like Zimmer Biomet Holdings Inc. NYSE: ZBH that manufacture joint-replacement technologies.

Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand

The notable rise in Boston Scientific's revenues in the recent past has also contributed to the stock's outperformance.

What's Next For Boston Scientific Stock After Outperforming During The 2022 Inflation Shock?

Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.

Boston Scientific (BSX) Rises 26.4%: Will the Rally Continue?

MARLBOROUGH, Mass. , May 30, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today that its Series A 5.50% Mandatory Convertible Preferred Stock (the preferred stock) will automatically convert into shares of the company's common stock on June 1, 2023.

Boston Scientific Announces Conversion Date of Series A Mandatory Convertible Preferred Stock

Celsius Holdings

Clean Harbors

Copa Hlds

Dynatrace Inc

Shockwave Medical

Wingstop

Several IBD 50 stocks are forming bullishly tight chart patterns. The post These Growth Stocks Seem Stalled.

These Growth Stocks Seem Stalled. That May Be A Good Thing.

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

Why Is Boston Scientific (BSX) Down 0.9% Since Last Earnings Report?

Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.

Boston Scientific (BSX) Gains From Acquisitions, New Launches

Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System* Results from global trial of the POLARx™ Cryoablation System* meet safety and effectiveness endpoints MARLBOROUGH, Mass. , May 20, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company's key electrophysiology and cardiac rhythm management therapies, and the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.

Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies

Shockwave Medical Inc. NASDAQ: SWAV, the largest component within the iShares Russell 2000 ETF NYSEARCA: IWM, briefly cleared a cup-with-handle buy point on May 12, but reversed lower along with the broader market.

Shockwave Medical, Fast Grower, In Boston Scientific's Sights?

MARLBOROUGH, Mass. , May 15, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023.

Boston Scientific to Participate in Bernstein's 39th Annual Strategic Decisions Conference

Boston Scientific (BSX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BSX crossed above the 20-day moving average, suggesting a short-term bullish trend.

Boston Scientific (BSX) Just Overtook the 20-Day Moving Average

The rumored matchup between Boston Scientific and Shockwave Medical reportedly broke down on Monday, leading SWAV stock into a dive. The post Shockwave Tumbles As Boston Scientific Takeover Talk Reportedly Breaks Down appeared first on Investor's Business Daily.

Shockwave Tumbles As Boston Scientific Takeover Talk Reportedly Breaks Down

Insulet

Stryker

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.

4 Medical Products Stocks to Capitalize on the Industry's Recovery

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Can Boston Scientific Set Another Net High?

Boston Scientific Corporation (BSX) Q1 2023 Earnings Call Transcript.

Boston Scientific Corporation (BSX) Q1 2023 Earnings Call Transcript

Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.

Boston Scientific (BSX) Q1 Earnings Beat, 2023 View Raised

The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Boston Scientific (BSX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Boston Scientific (BSX) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.39 per share a year ago.

Boston Scientific (BSX) Q1 Earnings and Revenues Surpass Estimates

Boston Scientific reported better-than-expected first-quarter growth on Tuesday, pushing BSX stock closer to a profit-taking zone. The post Boston Scientific Approaches A Profit-Taking Zone On First-Quarter Beat appeared first on Investor's Business Daily.

Boston Scientific Approaches A Profit-Taking Zone On First-Quarter Beat

Boston Scientific (NYSE:BSX) has reported first-quarter revenue and earnings that beat its own guidance as well as Wall Street's expectations due to strong growth at its MedSurg and Cardiovascular units, sending its shares higher in pre-market trading.  The Marlborough, Massachusetts-based medical products company said net sales increased 12% to $3.39 billion on a reported basis for the three months to March 31, 2023, above its guidance range of 3% to 5%.

Boston Scientific reports 1Q sales and earnings above guidance

Shares of Boston Scientific Corp. BSX jumped 2.8% into record territory in premarket trading Wednesday, after the medical technology company reported first-quarter results that beat expectations and raised its full-year outlook, citing a “robust pipeline” in 2023 and beyond. Net income jumped to $300 million, or 21 cents a share, from $97 million, or 7 cents a share, in the year-ago period.

Boston Scientific stock jumps into record territory after earnings beat, raised outlook

MARLBOROUGH, Mass. , April 26, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational1 basis and 14.0 percent on an organic2 basis, all compared to the prior year period.

Boston Scientific Announces Results for First Quarter 2023

A rise in elective surgeries performed and market share gains for some of its products will likely aid the company's top-line growth.

News for Boston Scientific Stock (BSX)